Cervical cancer is the second most common cancer among women worldwide. Research Human cancers generally develop through several steps -- initiation, promotion, and progression -- which require the accumulation of between 4 to 6 genetic mutations. Skin cancer is the most common cancer for both men and women. John DiGiovanni and colleagues, at The University of Texas MD Anderson Cancer Center, now show that a protein called Stat3 is required for skin cancer initiation and promotion.
Stat3 is a protein that normally acts to regulate the expression several genes in the cell. Stat3, when it is improperly activated, is known to be involved in a number of human cancers. Here researchers used a two-stage chemical skin cancer mouse model to investigate whether Stat3 is involved in one of the most common forms of cancer, and if so, at what stage.
They found that while a normal mouse, after chemical treatment, developed skin tumors, mice that were deficient in Stat3 were completely resistant to skin tumor development. The authors further showed, both in cell culture and in live animals, that they could block growth of already transformed skin cells if they inhibited Stat3 function using an oligonucleotide inhibitor. Additionally, when skin tumors were injected with this Stat3 functional inhibitor, tumor growth itself was impaired.
This study provides the first evidence that Stat3 is required for the initiation of one form of skin cancer, and that it both mediates and maintains cellular growth through expansion of these initiated cells. These data also indicate that Stat3, which has recently begun to emerge as a target for cancer therapy, may also be important for developing cancer prevention strategies.
Page: 1 Related biology news :1
Contact: Laurie Goodman
Journal of Clinical Investigation
. Stopping internal bleeding without surgery2
. Stopping "Cellular Suicide" Could Boost Production In Biotech Labs3
. Leader in cancer treatment and prevention research honored4
. International study findings link acne-like rash to effectiveness of new targeted cancer treatment5
. Chemical derived from vitamin-E shows early promise as cancer drug6
. New molecular link key to cellular proteins involved in cancer progression, other diseases7
. Phase II trials of second-generation antisense cancer drug planned following successful early study8
. Trial shows which brain cancer patients benefit from temozolomide9
. Genetic differences might help distinguish thyroid cancers10
. Evidence builds for potential new cancer drug target11
. New sequence involved in DNA replication timing may aid in cancer detection